Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 33 articles:
HTML format



Single Articles


    September 2021
  1. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed     Abstract available


  2. KAKOURATOS C, Kalamida D, Lamprou I, Xanthopoulou E, et al
    Apalutamide radio-sensitisation of prostate cancer.
    Br J Cancer. 2021 Sep 1. pii: 10.1038/s41416-021-01528.
    PubMed     Abstract available


    July 2021
  3. DE GIORGI U, Sansovini M, Severi S, Nicolini S, et al
    Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
    Br J Cancer. 2021 Jul 31. pii: 10.1038/s41416-021-01508.
    PubMed     Abstract available


  4. ZHAO Z, Zhao S
    Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 Jul 20. pii: 10.1038/s41416-021-01493.
    PubMed    


  5. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed     Abstract available


  6. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available


    June 2021
  7. SJOBERG HT, Philippou Y, Magnussen AL, Tullis IDC, et al
    Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Br J Cancer. 2021 Jun 21. pii: 10.1038/s41416-021-01450.
    PubMed     Abstract available


  8. LAN T, Park Y, Colditz GA, Liu J, et al
    Adolescent animal product intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01463.
    PubMed     Abstract available


    May 2021
  9. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.
    PubMed    


  10. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed     Abstract available


  11. FILON M, Gawdzik J, Truong A, Allen G, et al
    Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01398.
    PubMed     Abstract available


    April 2021
  12. EMOND JP, Lacombe L, Caron P, Turcotte V, et al
    Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01376.
    PubMed     Abstract available


    February 2021
  13. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    January 2021
  14. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    Correction: miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2021 Jan 13. pii: 10.1038/s41416-020-01258.
    PubMed    


    December 2020
  15. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
    Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01197.
    PubMed     Abstract available


  16. LIU S, Shen M, Hsu EC, Zhang CA, et al
    Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
    Br J Cancer. 2020 Dec 8. pii: 10.1038/s41416-020-01200.
    PubMed     Abstract available


  17. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  18. ZHAO Z, Zhao S, Luo L, Xiang Q, et al
    miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01187.
    PubMed     Abstract available


    October 2020
  19. LOZANO R, Castro E, Aragon IM, Cendon Y, et al
    Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01114.
    PubMed     Abstract available


  20. LI T, Liu N, Gao Y, Quan Z, et al
    Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01091.
    PubMed     Abstract available


    September 2020
  21. MOUT L, Moll JM, Chen M, de Morree ES, et al
    Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Br J Cancer. 2020 Sep 29. pii: 10.1038/s41416-020-01105.
    PubMed     Abstract available


  22. WANG LP, Chen TY, Kang CK, Huang HP, et al
    BCAS2, a protein enriched in advanced prostate cancer, interacts with NBS1 to enhance DNA double-strand break repair.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01086.
    PubMed     Abstract available


  23. PEREZ-CORNAGO A, Fensom GK, Andrews C, Watts EL, et al
    Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
    Br J Cancer. 2020 Sep 23. pii: 10.1038/s41416-020-01081.
    PubMed     Abstract available


  24. NASTALY P, Stoupiec S, Popeda M, Smentoch J, et al
    EGFR as a stable marker of prostate cancer dissemination to bones.
    Br J Cancer. 2020 Sep 9. pii: 10.1038/s41416-020-01052.
    PubMed     Abstract available


    August 2020
  25. HAESE A, Tin AL, Carlsson SV, Sjoberg DD, et al
    A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.
    Br J Cancer. 2020;123:604-609.
    PubMed     Abstract available


    July 2020
  26. CONTEDUCA V, Wetterskog D, Scarpi E, Romanel A, et al
    Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0969.
    PubMed     Abstract available


  27. NOBLE SM, Garfield K, Lane JA, Metcalfe C, et al
    The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0978.
    PubMed     Abstract available


  28. PHILIPPOU Y, Sjoberg HT, Murphy E, Alyacoubi S, et al
    Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Br J Cancer. 2020 Jul 9. pii: 10.1038/s41416-020-0956.
    PubMed     Abstract available


    June 2020
  29. LI L, Hobson L, Perry L, Clark B, et al
    Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
    Br J Cancer. 2020 Jun 25. pii: 10.1038/s41416-020-0951.
    PubMed     Abstract available


    May 2020
  30. FENG X, Song M, Preston MA, Ma W, et al
    The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0910.
    PubMed     Abstract available


  31. HUR J, Giovannucci E
    Racial differences in prostate cancer: does timing of puberty play a role?
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0897.
    PubMed     Abstract available


  32. BUTLER EN, Kelly SP, Coupland VH, Rosenberg PS, et al
    Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.
    Br J Cancer. 2020 May 20. pii: 10.1038/s41416-020-0859.
    PubMed     Abstract available


    September 2019
  33. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: